Analyst Reco. ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Real-time Estimate Cboe BZX Other stock markets 09:08:31 29/04/2024 pm IST			5-day change	1st Jan Change
17.22 ^USD	+3.08%		+0.68%	-45.37%

23/04	Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	MT
22/04	Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Adjusts Price Target on ACADIA Pharmaceuticals to $25 From $29, Maintains Overweight Rating	25/03	MT
UBS Adjusts ACADIA Pharmaceuticals Price Target to $33 From $35, Maintains Buy Rating	13/03	MT
Morgan Stanley Cuts Price Target on ACADIA Pharmaceuticals to $30 From $40 After Failed Study of Pimavanserin in Negative Symptoms of Schizophrenia; Overweight Kept	13/03	MT
Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $22 From $24, Maintains Hold Rating	12/03	MT
Cantor Fitzgerald Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $42, Maintains Overweight Rating	12/03	MT
Baird Adjusts Price Target on ACADIA Pharmaceuticals to $31 From $40, Maintains Outperform Rating	12/03	MT
Needham Lowers Price Target on ACADIA Pharmaceuticals to $32 From $36, Keeps Buy Rating	12/03	MT
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $19 From $25, Maintains Perform Rating	12/03	MT
Canaccord Genuity Adjusts Price Target on ACADIA Pharmaceuticals to $33 From $40, Keeps Buy Rating	12/03	MT
JMP Securities Cuts ACADIA Pharmaceuticals Price Target to $39 From $44, Maintains Market Outperform Rating	12/03	MT
RBC Cuts Price Target on ACADIA Pharmaceuticals to $30 From $35 After Phase 3 Trial of Pimavanserin Fails to Reach Primary Endpoint; Outperform Kept	12/03	MT
Mizuho Securities Downgrades ACADIA Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $25 From $39	12/03	MT
JPMorgan Cuts Price Target on ACADIA Pharmaceuticals to $29 From $32, Maintains Overweight Rating	01/03	MT
Deutsche Bank Trims ACADIA Pharmaceuticals Price Target to $24 From $25, Maintains Hold Rating	28/02	MT
Needham Trims Price Target on ACADIA Pharmaceuticals to $36 From $37, Maintains Buy Rating	28/02	MT
Mizuho Securities Adjusts Price Target on ACADIA Pharmaceuticals to $39 From $40, Maintains Buy Rating	28/02	MT
RBC Trims Price Target on ACADIA Pharmaceuticals to $35 From $36, Keeps Outperform Rating	28/02	MT
Baird Initiates ACADIA Pharmaceuticals With Outperform Rating, Price Target is $40	30/01	MT
Needham Upgrades ACADIA Pharmaceuticals to Buy From Hold, Price Target is $37	24/01	MT
RBC Boosts Price Target on ACADIA Pharmaceuticals to $36 From $33, Keeps Outperform Rating	03/01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Analyst Reco.

Filters